Longer Adjuvant Imatinib Therapy Better in High-Risk GIST: Risks of Recurrence, Death Reduced by More Than Half
Longer Adjuvant Imatinib Therapy Better in High-Risk GIST: Risks of Recurrence, Death Reduced by More Than Half
20110506
2011 Jun 6
Elsevier Global Medical News
Find more items about these cancer types:
Longer Adjuvant Imatinib Therapy Better in High-Risk GIST: Risks of Recurrence, Death Reduced by More Than Half
(00:04:07) Elsevier Global Medical News, 2011 Jun 6
Extending the duration of adjuvant imatinib therapy markedly improves outcomes in patients with resected gastrointestinal stromal tumor (GIST) who are at high risk for recurrence, a study presented at the American Society of Clinical Oncology (ASCO) annual meeting suggests.
/Images/Dr_Heikki_Joensuu_tcm8-269141.jpg
See related videos to:
ASCO 2011
Copyright © 2010 International Medical News Group
Subscribe Now »
Subscribe Now »
